Pamela Krueger

870 total citations
8 papers, 369 citations indexed

About

Pamela Krueger is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Pamela Krueger has authored 8 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Radiology, Nuclear Medicine and Imaging, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in Pamela Krueger's work include Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Pamela Krueger is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Pamela Krueger collaborates with scholars based in United States. Pamela Krueger's co-authors include Lynn E. Macdonald, Andrew Murphy, Jeanette Fairhurst, David M. Valenzuela, Nicholas Papadopoulos, Sean Stevens, George D. Yancopoulos, Lakeisha Esau, Anthony Doré and William Poueymirou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Pamela Krueger

6 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pamela Krueger United States	5	130	107	103	96	91	8	369
Lakeisha Esau United States	5	139 1.1×	103 1.0×	228 2.2×	73 0.8×	98 1.1×	6	495
Floris C. Loeff Netherlands	9	26 0.2×	125 1.2×	52 0.5×	47 0.5×	37 0.4×	23	331
J. Elsner Germany	8	37 0.3×	119 1.1×	42 0.4×	16 0.2×	44 0.5×	10	333
Barbara Giomi Italy	15	37 0.3×	224 2.1×	28 0.3×	39 0.4×	48 0.5×	36	740
Joseena Iype Switzerland	9	32 0.2×	154 1.4×	93 0.9×	29 0.3×	28 0.3×	12	379
Meijer Cj Netherlands	8	17 0.1×	95 0.9×	62 0.6×	115 1.2×	34 0.4×	16	396
Michael Tarzi United Kingdom	12	159 1.2×	197 1.8×	46 0.4×	10 0.1×	201 2.2×	17	563
Evangelia Michailidou Greece	8	56 0.4×	59 0.6×	143 1.4×	12 0.1×	14 0.2×	13	361
Brian Whitaker United States	9	41 0.3×	121 1.1×	126 1.2×	126 1.3×	18 0.2×	11	348
Yang Seok Chae South Korea	13	54 0.4×	34 0.3×	91 0.9×	12 0.1×	12 0.1×	32	482

Countries citing papers authored by Pamela Krueger

Since Specialization

Citations

This map shows the geographic impact of Pamela Krueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Krueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Krueger more than expected).

Fields of papers citing papers by Pamela Krueger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Krueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Krueger. The network helps show where Pamela Krueger may publish in the future.

Co-authorship network of co-authors of Pamela Krueger

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Krueger. A scholar is included among the top collaborators of Pamela Krueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Krueger. Pamela Krueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Jiang, Zaoli, Michael Rosconi, Bojie Zhang, et al.. (2024). A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants. Cancer Research. 84(13). 2169–2180. 3 indexed citations

2.

Zhu, Min, Alison Crawford, Jurriaan Brouwer‐Visser, et al.. (2024). Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer. Clinical and Translational Science. 17(12).

3.

Chiu, Danica, Richard Tavaré, Lauric Haber, et al.. (2020). A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunology Research. 8(5). 596–608. 33 indexed citations

4.

Jeong, Youngjae, et al.. (2020). Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta. Journal of Bone and Mineral Research. 37(5). 938–953. 13 indexed citations

5.

Varghese, Bindu, Jayanthi Menon, Luis Rodríguez, et al.. (2015). CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3. Blood. 126(23). 818–818.

6.

Murphy, Andrew, Lynn E. Macdonald, Sean Stevens, et al.. (2014). Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proceedings of the National Academy of Sciences. 111(14). 5153–5158. 307 indexed citations

7.

Krueger, Pamela, et al.. (2003). A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells. Cancer Immunology Immunotherapy. 52(6). 367–377. 7 indexed citations

8.

Krueger, Pamela, et al.. (2001). Monoclonal Antibody Identifies a Distinctive Epitope Expressed by Human Multiple Myeloma Cells. Journal of Immunotherapy. 24(4). 334–344. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact